1 week Ago By ABMN Staff
Aldeyra Therapeutics, Inc ( NASDAQ:ALDX – Get Free Report ) major shareholder Perceptive Advisors Llc sold 3,400,000 shares of the stock in a transaction that occurred on Thursday, April 3rd. The shares were sold at an average price of $1.42, for a total value of $4,828,000.
00. Following the completion of the sale, the insider now directly owns 5,875,851 shares of the company’s stock, valued at approximately $8,343,708.42.
This represents a 36.65 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website .
Major shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC. Aldeyra Therapeutics Trading Down 1.5 % Aldeyra Therapeutics stock opened at $1.
92 on Wednesday. Aldeyra Therapeutics, Inc has a one year low of $1.14 and a one year high of $7.
20. The business has a fifty day moving average of $5.81 and a two-hundred day moving average of $5.
36. The company has a debt-to-equity ratio of 0.18, a current ratio of 6.
80 and a quick ratio of 6.80. Aldeyra Therapeutics ( NASDAQ:ALDX – Get Free Report ) last announced its earnings results on Thursday, March 6th.
The biotechnology company reported ($0.27) EPS for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.
30). Research analysts forecast that Aldeyra Therapeutics, Inc will post -0.92 EPS for the current fiscal year.
Analyst Ratings Changes View Our Latest Research Report on Aldeyra Therapeutics Hedge Funds Weigh In On Aldeyra Therapeutics Hedge funds have recently made changes to their positions in the business. Hsbc Holdings PLC purchased a new position in shares of Aldeyra Therapeutics in the fourth quarter valued at $52,000. Balyasny Asset Management L.
P. acquired a new position in shares of Aldeyra Therapeutics in the 4th quarter worth approximately $56,000. Paloma Partners Management Co bought a new stake in Aldeyra Therapeutics during the third quarter valued at $62,000.
Catalyst Funds Management Pty Ltd lifted its holdings in Aldeyra Therapeutics by 2,083.3% in the fourth quarter. Catalyst Funds Management Pty Ltd now owns 13,100 shares of the biotechnology company’s stock worth $65,000 after acquiring an additional 12,500 shares during the last quarter.
Finally, Regal Investment Advisors LLC bought a new stake in shares of Aldeyra Therapeutics in the 4th quarter worth approximately $66,000. Hedge funds and other institutional investors own 59.71% of the company’s stock.
Aldeyra Therapeutics Company Profile ( Get Free Report ) Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Further Reading Receive News & Ratings for Aldeyra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics and related companies with MarketBeat.
com's FREE daily email newsletter ..
